AstraZeneca to Delist from Nasdaq, Transition to NYSE Listing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3h ago
0mins
Source: Benzinga
- Delisting Plan: AstraZeneca announced its voluntary delisting from Nasdaq, with trading ceasing on January 30, 2026, as part of a strategy to unify its global listing structure to attract a broader investor base.
- Listing Timeline: The company's ordinary shares and affected debt securities are expected to begin trading on the NYSE on February 2, 2026, allowing investors to trade across the London Stock Exchange, Nasdaq Stockholm, and NYSE.
- Cancer Drug Update: AstraZeneca's Enhertu has received validation for its marketing authorization application from the EMA, marking the start of the scientific review process and potentially offering new treatment options for HER2-positive breast cancer patients.
- Clinical Trial Results: In the DESTINY-Breast09 phase 3 trial, Enhertu in combination with pertuzumab demonstrated a statistically significant improvement in progression-free survival compared to traditional therapies, reinforcing its market potential.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 94.390
Low
95.00
Averages
102.75
High
108.00
Current: 94.390
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
